Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The Novo Nordisk Foundation is doubling down on metabolic disease research with a $53 million commitment to expand the Center for Genomic Mechanisms of Disease at the Broad Institute. The funding will supercharge efforts to decode the genetics of type 2 diabetes and obesity using AI, large-scale cellular data, and transatlantic collaboration. The goal: move from spotting genetic risk variants to actually understanding — and predicting — how they disrupt human biology.
The Novo Nordisk Foundation is putting $53 million behind a renewed push to understand the genetic roots of type 2 diabetes and obesity. The funding renews and expands the Center for Genomic Mechanisms of Disease at the Broad Institute, a transatlantic collaboration launched in 2021 with an initial $47.5 million grant. The Center unites genomic and computational expertise from the Broad with metabolic and population research strengths from Danish institutions.
The next phase shifts from building infrastructure to deploying it at scale. Researchers plan to generate hundreds of millions of detailed cell profiles — including fat and brain cells grown from stem cells — and use that data to train specialized AI models capable of predicting how DNA changes disrupt cellular health. Denmark's AI supercomputer Gefion, one of the world's most powerful GPU clusters, will provide the computing muscle.
By the Numbers:
Why it matters: Diabetes and obesity are the leading causes of death globally, yet their underlying biology remains poorly understood. By combining human genetics, AI, and large-scale experimentation, this collaboration could uncover entirely new disease subtypes and drug targets — potentially helping millions of patients who don't respond to existing treatments.
